journal article·2023-04Open access

An “AND” Molecular Logic Gate as a Super‐Enhancers for De Novo Designing Activatable Probe and Its Application in Atherosclerosis Imaging

Mangmang Sang, Yibo Huang, Lu Wang, Lei Chen, Nawsherwan, Gang Li, Yan Wang, Xiu Yu, Cuilian Dai, Jinrong Zheng

Advanced Science· Volume 10· Issue 12

Abstract

Abstract Developing activatable fluorescent probes with superlative fluorescence enhancement factor (F/F0) to improve the signal‐to‐noise (S/N) ratio is still an urgent issue. “AND” molecular logic gates are emerging as a useful tool for enhanced probes selectivity and accuracy. Here, an “AND” logic gate is developed as super‐enhancers for designing activatable probes with huge F/F0 and S/N ratio. It utilizes lipid‐droplets (LDs) as controllable background input and sets the target analyte as variable input. The fluorescence is tremendously quenching due to double locking, thus an extreme F/F0 ratio of target analyte is obtained. Importantly, this probe can transfer to LDs after a response occurs. The target analyte can be directly visualized through the spatial location without a control group. Accordingly, a peroxynitrite (ONOO−) activatable probe (CNP2‐B) is de novo designed. The F/F0 of CNP2‐B achieves 2600 after reacting with ONOO−. Furthermore, CNP2‐B can transfer from mitochondria to lipid droplets after being activated. The higher selectivity and S/N ratio of CNP2‐B are obtained than commercial probe 3'‐(p‐hydroxyphenyl) fluorescein (HPFin vitro and in vivo. Therefore, the atherosclerotic plaques at mouse models are delineated clearly after administration with in situ CNP2‐B probe gel. Such input controllable “AND” logic gate is envisioned to execute more imaging tasks.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Cardiovascular Diseases Xiamen Cardiovascular Hospital of Xiamen University School of Medicine Xiamen University No. 2999 Jinshan Road, Huli District Xiamen 361006 China

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine Nanjing University of Chinese Medicine No. 157, Daming Road, Qinhuai District Nanjing 210000 China

School of Pharmacy Gannan Medical University No. 1 Medical College Road, Zhanggong District Ganzhou 341000 China

Shenzhen Key Laboratory of Respiratory Diseases Shenzhen People's Hospital Southern University of Science and Technology 3046 Shennan East Road, Luohu District Shenzhen 518055 China

Funding

National Natural Science Foundation of China

References (39)

Show source-provided references
1. 10.1161/CIRCRESAHA.119.31593910.1161/CIRCRESAHA.119.315939 ↗
2. 10.1053/j.semvascsurg.2020.11.00110.1053/j.semvascsurg.2020.11.001 ↗
3. 10.1016/j.ejso.2016.06.38910.1016/j.ejso.2016.06.389 ↗
4. 10.1016/S1470-2045(11)70130-910.1016/S1470-2045(11)70130-9 ↗
5. 10.1148/radiol.1210239410.1148/radiol.12102394 ↗
6. 10.1021/jacs.0c0702210.1021/jacs.0c07022 ↗
7. 10.1002/anie.20170697410.1002/anie.201706974 ↗
8. 10.3171/jns.1948.5.4.039210.3171/jns.1948.5.4.0392 ↗
9. 10.1007/s00595-019-01906-610.1007/s00595-019-01906-6 ↗
10. 10.3389/fped.2020.0031410.3389/fped.2020.00314 ↗
11. 10.21037/atm.2016.10.7010.21037/atm.2016.10.70 ↗
12. 10.1002/smll.20200221110.1002/smll.202002211 ↗
13. 10.1016/j.bios.2018.08.01410.1016/j.bios.2018.08.014 ↗
14. 10.1021/acs.chemrev.9b0037910.1021/acs.chemrev.9b00379 ↗
15. 10.1002/adfm.20200635310.1002/adfm.202006353 ↗
16. 10.7150/thno.2385310.7150/thno.23853 ↗
17. 10.1021/acsnano.9b0820910.1021/acsnano.9b08209 ↗
18. 10.1016/j.nantod.2020.10090510.1016/j.nantod.2020.100905 ↗
19. 10.1021/acsami.8b0984110.1021/acsami.8b09841 ↗
20. 10.1021/jacs.0c0136510.1021/jacs.0c01365 ↗
21. 10.1089/lap.2020.039910.1089/lap.2020.0399 ↗
22. 10.1016/j.biomaterials.2017.12.00210.1016/j.biomaterials.2017.12.002 ↗
23. 10.1039/C9CC07694H10.1039/C9CC07694H ↗
24. 10.1039/C7SC00251C10.1039/C7SC00251C ↗
25. 10.1038/s41467-018-05113-810.1038/s41467-018-05113-8 ↗
26. 10.1038/s41551-020-0536-710.1038/s41551-020-0536-7 ↗
27. 10.1016/j.snb.2020.12905010.1016/j.snb.2020.129050 ↗
28. 10.1002/adma.20200003710.1002/adma.202000037 ↗
29. Maguire E. M. · Vasc. Pharmacol. · 2018 · 112
30. 10.3892/mmr.2016.509910.3892/mmr.2016.5099 ↗
31. 10.1039/D1TB00335F10.1039/D1TB00335F ↗
32. 10.1016/j.cclet.2021.02.05910.1016/j.cclet.2021.02.059 ↗
33. 10.1021/acs.analchem.8b0407910.1021/acs.analchem.8b04079 ↗
34. Li F. · Mol. Med. Rep. · 2018 · 18 · 1973
35. 10.1186/s12885-015-1546-910.1186/s12885-015-1546-9 ↗
36. 10.3390/ijms2023609310.3390/ijms20236093 ↗
37. 10.1021/jacs.1c0795410.1021/jacs.1c07954 ↗
38. 10.1002/anie.20220689410.1002/anie.202206894 ↗
39. 10.1021/acs.analchem.2c0149610.1021/acs.analchem.2c01496 ↗